Presage Biosciences, Inc. announced that it will receive $15,840,000 in funding on March 1, 2013. The company will issue equity securities in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. On March 5, 2013, the company announced that it has received $8,000,000 in first tranche of the transaction. New investor, Celgene Corporation participated for the whole amount. The investor will also provide the investor with ... $5,000,000 for research support and will make future investments if the company’s technology helps the investor attain certain goals. The investor has acquired less than controlling stake in the company. Jones Day will act as legal advisor to Celgene Corporation with a team led by John Beeson.
Read More

Sponsored Financial Commentaries

To contact CELGENE CORP-CVR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.